Skip to main content
Evidence Snapshot

Melanocortin receptor 4

CHEMBL259 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:48:27Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL259
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Melanocortin receptor 4 as ChEMBL target CHEMBL259, mapped to UniProt P32245. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Melanocortin receptor 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL259
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P32245
Melanocortin receptor 4
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Melanocortin receptor 4 matters

As of 2026-09-13

Melanocortin receptor 4 is reviewed as Melanocortin receptor 4 (UniProt P32245); Melanocortin receptor 4 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 20 approved drugs, 5161 compounds, and 630 assays, with lead potency reaching pChEMBL 10.8.

Disease context
obesity

Melanocortin receptor 4 shows approved-linked disease relevance led by obesity. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include SETMELANOTIDE, SETMELANOTIDE ACETATE.

Start review with obesity because it currently carries approved-linked support. Linked drugs include SETMELANOTIDE, SETMELANOTIDE ACETATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 20 approved drugs, 5161 compounds, and 630 assays for this target. The dominant activity type is KI. CHEMBL4798971 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL4798971 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
20 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Melanocortin receptor 4 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P32245, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why obesity is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5161
Total Compounds
630
Total Assays
20
Approved Drugs
IC50: 2232.0, KI: 3640.0, EC50: 2070.0, KD: 31.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4798971
 10.8 Ki —
No preferred name
CHEMBL4794168
 10.8 Ki —
No preferred name
CHEMBL4794121
 10.8 Ki —
No preferred name
CHEMBL441738
 10.8 EC50 Approved
No preferred name
CHEMBL413212
 10.7 EC50 —

Approved Drugs

Structure Compound First Approval
SETMELANOTIDE
CHEMBL3301624
 2020
BREMELANOTIDE
CHEMBL2070241
 2019
AFAMELANOTIDE
CHEMBL441738
 2014
COSYNTROPIN
CHEMBL2103784
 1970
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T11:48:27Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL259